Enter vial size, bacteriostatic water volume and a quantity per administration to get concentration, syringe units and draws per vial. KPV has no established dose — this page does the arithmetic, not the recommendation. The compound itself is covered in the KPV peptide guide.
A 10 mg vial of KPV reconstituted with 2 mL of bacteriostatic water gives a concentration of 5 mg/mL, or 50 mcg per unit on a U-100 syringe. For a 1 mg quantity, draw the syringe to 20 units (0.20 mL). At that quantity the vial provides about 10 draws. KPV has no established dose; this is arithmetic on a quantity you supply.
Draw the syringe up to
That's one 250 mcg dose. Add 1 mL of water to your 5 mg vial first.
KPV is a three-amino-acid peptide, Lys-Pro-Val, the C-terminal fragment of α-MSH at roughly 342 daltons. Its anti-inflammatory activity is documented in mouse models, not in people: no human clinical trial of KPV has been published as of August 2026, and none has established a quantity by any route. That is why the input above is a reference quantity. A calculator that printed a KPV dose would be inventing the one number the evidence does not supply.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is KPV? | The C-terminal tripeptide of α-MSH, α-MSH(11-13); sequence Lys-Pro-Val; molecular weight ~342 Da | Chemical identity |
| How does it act? | Inhibits NF-κB signalling, reduces pro-inflammatory cytokine production, and modulates immune cell function | Mechanism, preclinical |
| What has been shown? | In murine models, KPV produced significant anti-inflammatory effects in two models of colitis | Animal model |
| Why might oral work? | Its small size and uptake by the intestinal peptide transporter PepT1 give it more plausible oral activity than longer peptides; orally administered KPV reduced colitis in mouse models | Animal model, mechanism |
| Human trials? | No human clinical trials of KPV have been published as of August 2026 | None |
| An oral dose? | There are no human trials establishing an oral dose or effect | None |
| A recommended dose? | Does Peptigrity recommend a KPV dose? No | None — declined |
| Routes in the market | Injectable, oral and topical formulations are all represented in research-grade vendor markets | Market observation, not efficacy |
KPV's evidence base is preclinical and murine — two colitis models, IBD, skin-barrier and periodontal work — with no published human clinical trial as of August 2026, no established oral dose or effect, long-term safety uncharacterised, and no Peptigrity dose recommendation. Injectable, oral and topical formulations all exist in the vendor market; this page calculates for the injectable route only, because units on a U-100 syringe is a subcutaneous-injection question and the arithmetic has no meaning for a capsule or a cream.
KPV draw volumes depend entirely on the concentration you mixed and the quantity you intend. At the default of 5 mg/mL, 250 mcg is 5 units, 500 mcg is 10 units, 1 mg is 20 units and 2 mg is 40 units — all comfortably inside a 1 mL U-100 barrel. The table below is a conversion grid, not an escalation ladder.
| Quantity per administration | Draw at 5 mg/mL | Volume | Draws from a 10 mg vial | Draws from a 30 mg vial |
|---|---|---|---|---|
| 250 mcg | 5 units | 0.05 mL | 40 | 120 |
| 500 mcg | 10 units | 0.10 mL | 20 | 60 |
| 1 mg (page reference) | 20 units | 0.20 mL | 10 | 30 |
| 2 mg | 40 units | 0.40 mL | 5 | 15 |
| 5 mg | 100 units | 1.00 mL | 2 | 6 |
These rows are arithmetic reference points spanning the range a U-100 syringe reads well at this concentration. They are not tiers, not a schedule, and not doses. No trial, label or Peptigrity guidance establishes a KPV quantity. In sentences: 250 mcg — draw 5 units (0.05 mL) at 5 mg/mL, and a 10 mg vial gives 40 such draws. 500 mcg — 10 units (0.10 mL), 20 draws. 1 mg — 20 units (0.20 mL), 10 draws. 2 mg — 40 units (0.40 mL), 5 draws. 5 mg — 100 units (1.00 mL), which fills a 1 mL barrel exactly, 2 draws.
At 5 mg/mL a 250 mcg quantity is 5 units, and a misread of one unit is a 20% error on the amount drawn. If you are working at the small end of this grid the fix is more diluent, not a steadier hand: the same 250 mcg from a 10 mg vial in 5 mL is 12.5 units, which is a reading a person can actually make. Arithmetic, shown: at 2 mg/mL, 250 mcg ÷ 20 mcg per unit = 12.5 units.
KPV vials in the tracked market run from 4 mg to 80 mg, so the same quantity can land anywhere on the barrel depending on which vial you hold and how much water you added. Read down the column for your concentration, not across — a units figure carried from one concentration to another is simply wrong.
| Quantity | At 2 mg/mL (10 mg + 5 mL) | At 5 mg/mL (10 mg + 2 mL) | At 10 mg/mL (10 mg + 1 mL) |
|---|---|---|---|
| 250 mcg | 12.5 units | 5 units | 2.5 units |
| 500 mcg | 25 units | 10 units | 5 units |
| 1 mg | 50 units | 20 units | 10 units |
| 2 mg | 100 units | 40 units | 20 units |
| 5 mg | — exceeds a 1 mL barrel (250 units) | 100 units | 50 units |
Every cell is the same arithmetic: units = (quantity mg ÷ concentration mg/mL) × 100. At 10 mg/mL every quantity in this grid up to 5 mg fits inside a single 1 mL U-100 barrel; at 2 mg/mL only quantities up to 2 mg do, and quantities at or below 250 mcg become hard to read accurately at the higher concentrations.
KPV reconstitution is a choice, not a recipe. No approved label sets a diluent volume for KPV and no source page states one, so the volume you pick is the one that puts your intended quantity in a readable part of the syringe. The decision with real consequences is resolution: a 10 mg vial in 1 mL puts a 250 mcg draw at 2.5 units, where a misread of one unit is a 40% error. Technique is covered once, elsewhere: reconstituting peptides step by step and the bacteriostatic water guide.
A KPV vial lasts as many administrations as the label mass divided by the quantity per administration — the water volume changes nothing about it. The grid counts draws, not weeks: convert to a duration yourself, because this page states no frequency. No source establishes how often KPV is administered.
| Vial size | At 250 mcg | At 500 mcg | At 1 mg | At 2 mg | At 5 mg |
|---|---|---|---|---|---|
| 4 mg | 16 draws | 8 draws | 4 draws | 2 draws | — |
| 5 mg | 20 draws | 10 draws | 5 draws | 2.5 draws | 1 draw |
| 10 mg | 40 draws | 20 draws | 10 draws | 5 draws | 2 draws |
| 30 mg | 120 draws | 60 draws | 30 draws | 15 draws | 6 draws |
| 80 mg | 320 draws | 160 draws | 80 draws | 40 draws | 16 draws |
Arithmetic: draws per vial = vial mg ÷ quantity mg. A 10 mg KPV vial gives about 10 draws at 1 mg per administration. A 30 mg vial gives about 30 at the same quantity. A 4 mg vial gives about 4. An 80 mg vial gives about 80. Multiply by your own frequency to get a duration; this page does not supply one.
KPV is not approved for any medical indication anywhere in the world as of May 2026, and it is sold as a research-use-only compound. Its regulatory position moved twice in 2026 and neither move was an approval: on 22 April 2026 the FDA removed KPV from its Category 2 bulk drug substances list, a procedural step, and at the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026 the committee voted 8–6–1 to recommend KPV for the 503A compounding bulks list. FDA scientific staff opposed that recommendation, the committee's role is advisory, and the agency has not finalised anything.
KPV is legal as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption. Other compounds in the same category: other immune-support compounds. Independent test records: KPV lab test records. Tracked prices: KPV price per milligram.
It depends on the concentration. At the page default of 5 mg/mL (10 mg vial + 2 mL), 1 mg is 20 units on a U-100 syringe. At 10 mg/mL it is 10 units, and at 2 mg/mL it is 50 units. A units figure quoted without a concentration cannot be used.
There isn't one. No human clinical trial of KPV has been published as of August 2026, no trial has established a quantity by any route, no regulator has approved a dose, and Peptigrity does not recommend one. This calculator converts a quantity you supply into units on a syringe. It does not supply the quantity.
There is no standard volume and no label to specify one, so the choice is yours. 1 mL gives 10 mg/mL, 2 mL gives 5 mg/mL and 5 mL gives 2 mg/mL. Pick the one that puts your intended quantity in a readable part of the barrel rather than down at two or three units.
Its small size — three amino acids, about 342 daltons — and its uptake by the intestinal transporter PepT1 make oral activity more plausible than for longer peptides, and orally administered KPV reduced colitis in mouse models. That evidence is preclinical: there are no human trials establishing an oral dose or effect. This calculator covers injectable arithmetic only.
No. The Pharmacy Compounding Advisory Committee voted 8–6–1 in July 2026 to recommend KPV for the 503A compounding bulks list, but FDA scientific staff opposed it, the committee is advisory, and the agency has not finalised anything. KPV is not approved for any medical indication anywhere in the world.
No. The indexed tests establish high chemical purity, but net content is a separate measurement and recent tested quantities run from 9.48 mg to 12.21 mg against a 10 mg label. A certificate confirms identity and purity; it does not confirm the amount in your particular vial.